+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

Visiongain states that ‘Global Generic Drugs Market Set To Grow To $423.7bn By 2023’

30 July 2018
Pharma

Visiongain’ has launched a new pharma report Generic Drugs Market Forecast 2018-2028: Growth in Leading Regional and National Markets – North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America, US, Canada, Germany, France, UK, Italy, Spain, India, China, Australia, South Korea, Japan, South Africa, Saudi Arabia, U.A.E, Brazil, Argentina, Mexico

The generic drugs market has historically increased at near double-digit growth rates over the last three decades, compared to single-digit growth for the pharmaceutical market as a whole. The industry has benefited from increasing generic penetration in most major markets notable exceptions being Japan, France, Italy and Spain, where generic penetration is increasing slowly. This trend is likely to continue as falling R&D productivity begins to limit revenues for innovator companies while cost pressures encourage the growth of generic sales by volume.

The lead analyst of the report commented “The socio-economic landscape of many national and regional markets globally has been changing immensely over the last decade. This factor, coupled with the changing in the demographics of these regions will help to shape the future direction of generic drugs over the next 10 years. Population growth and ageing are expected to increase the burden of disease, especially chronic diseases such as diabetes and hypertension. This will be a major driver of the demand for generic medicines during the forecast period.”

Leading companies featured in the report include Teva, Novartis (Sandoz), Allergan, Mylan, Pfizer, Abbott, Sun Pharma, Aspen, Fresenius Kabi, Sanofi, Dr. Reddy’s Laboratories, Apotex

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 208 781 6953

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Drug Delivery Technologies Market Report 2024-2034

The global Drug Delivery Technologies market is estimated at US$1,729.6 billion in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period 2024-2034.

23 April 2024

Read

Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

18 April 2024

Read

Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

17 April 2024

Read

Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

12 April 2024

Read